NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.

Jaeckle, Kurt A.; Schiff, David; Anderson, S. K.; Galanis, E.; Stella, Philip J.; Flynn, Patrick J.; Sarkaria, Jann N.; Scheithauer, Bernd W.; Erickson, Brandon J.; Buckner, Jan C.; Ncctg,

doi:10.1200/jco.2011.29.15_suppl.2033

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an Austrian database, a similar improvement of OS was seen in the contemporary cohort treated with CRT (n = 375) compared with a historical control treated primarily with RT only [44]. Table 2 outlines the 12 clinical trials presented regarding the treatment of recurrent GBM (Table 2) [45][46][47][48][49][50][51][52][53][54][55][56]. In the only randomized trial, afatinib, an irreversible tyrosine kinase EGFR inhibitor, was compared with ddTMZ and to the combination of ddTMZ and afatinib in 120 patients with first recurrent GBM [45].…”

Section: Meeting Reportmentioning

confidence: 76%

“…Neuro-oncology: a selected review of ASCO 2011 abstracts (mPFS: 2.6 months; mOS 4.2 months) and toxic in 37 patients [48]. Similarly, a study of 36 patients with sorafenib and metronomic (low dose daily) TMZ demonstrated limited activity, similar to the aforementioned trial of sorafenib and temsirolimus [52].…”

Section: Meeting Reportmentioning

confidence: 94%

“…mOS was 6.1 months in the bevacizumab continuation group compared with 4.5 months in the bevacizumab discontinuation group, suggesting a marginal advantage to continuing bevacizumab. Four articles utilized novel agents to treat bevacizumab-naive patients with recurrent GBM [48,51,52,54]. A combination of sorafenib (a multifunctional tyrosine kinase inhibitor that has anti-VEGF receptor activity) and temsirolimus (an mTOR inhibitor) was found to be inactive …”

Section: Meeting Reportmentioning

confidence: 99%

See 2 more Smart Citations

Neuro-oncology: a selected review of ASCO 2011 abstracts

Chamberlain

2011

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Section: Meeting Reportmentioning

confidence: 76%

Section: Meeting Reportmentioning

confidence: 94%

Section: Meeting Reportmentioning

confidence: 99%

See 1 more Smart Citation

Neuro-oncology: a selected review of ASCO 2011 abstracts

Chamberlain

2011

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

“…Patients with recurrent or progressive glioblastoma received sorafenib 400 mg twice daily and erlotinib 150 mg once daily until progression. In this phase I/II study, the MTD was established for sorafenib at 200 mg twice daily and temsirolimus 20 mg/m 2 weekly [19]. Pharmacokinetic studies demonstrated a significant and potentially clinically important increase in the clearance of erlotinib by sorafenib that may negatively impact the efficacy of this combination regimen.…”

Section: Discussionmentioning

confidence: 99%

Sorafenib for patients with pretreated recurrent or progressive high-grade glioma

Hassler¹,

Ackerl²,

Flechl³

et al. 2014

Anti-Cancer Drugs

View full text Add to dashboard Cite

Therapeutic options for patients with pretreated advanced high-grade glioma (HGG) are limited. Sorafenib, a small molecule with multiple potential beneficial actions, appears particularly promising. We reviewed the outcomes of 30 patients with recurrent or progressive HGG treated with sorafenib within a named patient program. Overall, 16 patients suffered from recurrent or progressive glioblastoma multiforme and 14 patients had grade 3 gliomas. All but four patients had previously undergone surgical debulking; all but one patient had received previous standard multimodal treatment; and 18 patients (60%) had received more than one line of chemotherapy, in median three. Progression-free survival (PFS), defined as the time from initiation of sorafenib to treatment discontinuation because of tumor progression or death, was selected as the endpoint. The use of sorafenib resulted in a median PFS of 3 months [95% confidence interval (CI) 1.9-4.1 months] in patients with glioblastoma and of 3.1 months (95% CI 1.4-4.8 months) in patients with other HGG. The PFS-6 for the whole cohort was 23%. Sixteen patients reported adverse events, mostly moderate, with hypertension as the most frequently reported toxicity (seven patients). One patient died of cerebral bleeding (grade 5 toxicity). The overall survival after initiation of sorafenib was 6 months (95% CI 3.9-8.0 months) for patients with glioblastoma multiforme and 10 months (95% CI 3.1-16.9 months) for patients with HGG. In this retrospective analysis of heavily pretreated patients with HGG, sorafenib monotherapy was associated with tumor stabilization in a small subset of patients. The risk-benefit ratio was acceptable in the context of an apparent clinical benefit in patients with a fatal disease.

show abstract

“…PFS-6 was 9.4%, suggesting limited activity for recurrent GBM [73]. Preliminary results of a Phase I/II trial of sorafenib and temsirolimus in patients with recurrent GBM revealed a median time to progression of 2.6 months, again suggesting limited activity of sorafenib in recurrent GBM [74]. A Phase II trial of sorafenib added to standard radiotherapy and TMZ in newly diagnosed GBM patients did not appear to improve the efficacy when compared with the results expected with standard therapy [75].…”

Section: Sorafenibmentioning

confidence: 94%